RNA Interference-based Therapies for the Reduction of Cardiovascular Risk

Natalia      Nazarenko; Jiyoung      Seo; Sanjana      Nagraj; Leonidas      Palaiodimos; Damianos   G.   Kokkinidis

doi:10.2174/0118761429264553231204115314

Abstract

Globally, there remains an unwavering increase in the incidence of cvd - from 271 million in 1990 to 523 million in 2019. Among the several modifiable and non-modifiable risk factors of heart disease, dyslipidemia is an important and prevalent risk factor mediated by both genetics and lifestyle factors. Hence, lowering lipid levels, specifically, ldl-c levels (low-density lipoprotein cholesterol), is a key strategy in decreasing the risk of cardiovascular disease. A reduction of 20 mg/dl in ldl-c levels has been found to prevent 2-3 cases of coronary artery disease (cad) for every 1000 individuals. Studies have also found reductions in ldl-c levels to be associated with a mortality benefit. However, ldl-c levels reduction may not eliminate the risk of significant cardiovascular events.

Keywords: RNA interference, ASO, siRNA, Cardiovascular risk reduction, Lipid lowering therapy, LDL, Lp(a).

Download Options

Rights & Permissions Print Cite

Current Molecular Pharmacology

Title:RNA Interference-based Therapies for the Reduction of Cardiovascular Risk

Volume: 17

Author(s): Natalia Nazarenko, Jiyoung Seo, Sanjana Nagraj, Leonidas Palaiodimos and Damianos G. Kokkinidis*

Affiliation:

Section of Cardiovascular Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA

Keywords: RNA interference, ASO, siRNA, Cardiovascular risk reduction, Lipid lowering therapy, LDL, Lp(a).

Abstract: Globally, there remains an unwavering increase in the incidence of cvd - from 271 million in 1990 to 523 million in 2019. Among the several modifiable and non-modifiable risk factors of heart disease, dyslipidemia is an important and prevalent risk factor mediated by both genetics and lifestyle factors. Hence, lowering lipid levels, specifically, ldl-c levels (low-density lipoprotein cholesterol), is a key strategy in decreasing the risk of cardiovascular disease. A reduction of 20 mg/dl in ldl-c levels has been found to prevent 2-3 cases of coronary artery disease (cad) for every 1000 individuals. Studies have also found reductions in ldl-c levels to be associated with a mortality benefit. However, ldl-c levels reduction may not eliminate the risk of significant cardiovascular events.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Nazarenko Natalia, Seo Jiyoung, Nagraj Sanjana, Palaiodimos Leonidas and Kokkinidis G. Damianos*, RNA Interference-based Therapies for the Reduction of Cardiovascular Risk, Current Molecular Pharmacology 2024; 17 : e18761429264553 . https://dx.doi.org/10.2174/0118761429264553231204115314

DOI https://dx.doi.org/10.2174/0118761429264553231204115314	Print ISSN 1874-4672
Publisher Name Bentham Science Publisher	Online ISSN 1874-4702

About this journal

Call for Papers in Thematic Issues

Submission closes on : 02 November, 2024

Common mechanisms underpinning neurodevelopmental disorders and psychiatric diseases

A growing number of large-scale epidemiologic studies has strongly suggested that common mechanisms may be shared by aberrant brain development and psychiatric disorders. There is now an appreciation of synergic roles of genetic variants and environmental stress which profoundly affect the genome integrity and reshape brain development. This can lead ...read more

Guest Editor(s): Dr. BING LANG